MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ESPR had $6,386K increase in cash & cash equivalents over the period. -$4,286K in free cash flow.

Cash Flow Overview

Change in Cash
$6,386K
Free Cash flow
-$4,286K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-31,333 -53,180
Non-cash loss on extinguishment of debt
0 0
Non-cash royalty revenue
16,359 24,061
Paid-in-kind interest on long-term debt
4,580 4,406
Depreciation expense
26 53
Amortization of debt issuance costs and discounts
847 1,519
Non-cash interest expense related to the revenue interest liability
0 0
Non-cash interest expense related to the royalty sale liability
14,637 26,363
Stock-based compensation expense
2,349 5,134
Accounts receivable
11,234 27,604
Prepaids and other assets
6,176 15,718
Deferred revenue
8,366 13,795
Inventories
-5,927 19,975
Other long-term liabilities
0 7,436
Accounts payable
2,901 30,462
Other accrued liabilities
21,183 -2,680
Net cash (used in) provided by operating activities
-4,286 -54,050
Purchase of property and equipment
0 0
Net cash (used in) investing activities
0 0
Payments on revenue interest liability
0 0
Repurchase of revenue interest liability
0 0
Payment of royalty sale liability issuance costs
0 -
Proceeds from royalty sale liability
0 0
Proceeds from issuance of common stock, net of issuance costs
0 0
Proceeds from issuance of common stock from atm program, net of issuance costs
10,531 2,850
Proceeds from exercise of common stock options
141 0
Proceeds from exercise of warrants, net of issuance costs
0 0
Payment of issuance costs
0 7,500
Net cash provided by financing activities
10,672 -4,650
Net (decrease) increase in cash and cash equivalents
6,386 -58,700
Cash and cash equivalents at beginning of period
144,761 -
Cash and cash equivalents at end of period
92,447 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. (ESPR)